The Evolving Role of HER2-Targeting Therapies in Breast Cancer

Rebecca A. Shatsky, MD, provides an overview of the current methods for diagnosing HER2+ breast cancer, highlighting immunohistochemistry and in situ hybridization.

A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.

Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.

Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.

An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.

Dr Shatsky provides clinical insights on treatment sequencing for patients undergoing treatment for HER2-positive breast cancer.

Rebecca A. Shatsky, MD, looks to the future of HER2+ breast cancer treatment, highlighting unmet needs in the therapeutic space.